Clinical Trial Update: ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals [Phase 4]

View source ↗

Summary

The ORBITAL Phase 4 trial investigating rosuvastatin-based compliance initiatives to achieve LDL goals in primary hypercholesterolemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• CRESTOR (Rosuvastatin)

Snippet

Sponsor: AstraZeneca | Conditions: Primary Hypercholesterolaemia | Phase 4 | Status: WITHDRAWN